BD chief George Golumbes­ki is the lat­est top ex­ec to ex­it Cel­gene dur­ing man­age­ment over­haul

George Golumbes­ki (SO­TIO)

Over the past decade, George Golumbes­ki rose to be­come an ex­ec­u­tive vice pres­i­dent at Cel­gene, fre­quent­ly laud­ed for his high-pro­file role in lead­ing one of the most ag­gres­sive BD teams in biotech. 

But Golumbes­ki has qui­et­ly slipped out the back door at Cel­gene at a time CEO Mark Alles has been ex­e­cut­ing a se­ries of man­age­ment changes af­ter a string of prat­falls has been rais­ing ques­tions about the com­pa­ny’s com­pe­tence on ex­e­cut­ing on a longterm strat­e­gy.

Ac­cord­ing to a note on Golumbes­ki’s re­sume post­ed at Mor­phoSys AG, which just ap­point­ed him as a new su­per­vi­so­ry board mem­ber, the BD ex­ec of­fi­cial­ly left Cel­gene April 16, tran­si­tion­ing to a new role as an in­de­pen­dent con­sul­tant af­ter gath­er­ing a slate of new roles for his post-Cel­gene life. He’s al­so a sci­en­tif­ic ad­vis­er at new­ly launched KSQ, the start­up run by ex-Gen­zyme chief David Meek­er, and is list­ed as a ven­ture part­ner at ARCH.

In­vestors didn’t like the sound of it. Cel­gene’s stock plunged 5% af­ter the sto­ry came out.

The tran­si­tion last month, though, has been in the works for close to two and a half years, Golumbes­ki tells me to­day. That’s when he sat down with Bob Hug­in and Alles and some oth­ers to say that af­ter some 20 years on the deal side of the busi­ness, with more than 9 years at Cel­gene, he was ready to do some­thing new and dif­fer­ent.

“I com­mu­ni­cat­ed I was very hap­py to stay on,” he adds, “but in­tend­ed to leave in Q1 or Q2 2017.” For a va­ri­ety of rea­sons, his stay last­ed un­til April. And he em­pha­sizes his de­par­ture was com­plete­ly am­i­ca­ble all around.

Now Golumbes­ki has a va­ri­ety of new gigs, most­ly cen­tered on up and com­ing biotech com­pa­nies, where he plans to play a role in re­cruit­ing top ex­ecs, rais­ing mon­ey and fo­cus­ing on some game-chang­ing med­i­cines. And this way he al­so gets to spend more time with the fam­i­ly.

“I’m in a good place,” he adds. “I want to help to the ex­tent I can these young com­pa­nies.”

Cel­gene me­dia con­tacts nev­er re­spond­ed di­rect­ly to ques­tions abut Golumbes­ki’s de­par­ture.

Mark Alles

Work­ing un­der ex-Cel­gene CEO Bob Hug­in and in close part­ner­ship with ex-R&D chief Tom Daniel, Golumbes­ki was the chief ar­chi­tect of a strat­e­gy to snag a mul­ti­tude of drug rights in an ef­fort to ex­pand be­yond their block­buster Revlim­id. Cel­gene bought in­to Juno sev­er­al years ago, then fol­lowed up with a $9 bil­lion buy­out. Over­all, the com­pa­ny liked do­ing deals that left the part­ners in charge of the re­search, as they did suc­cess­ful­ly with Agios and oth­ers.

“We do a bet­ter job lis­ten­ing to what a part­ner has to say,” Golumbes­ki told me sev­er­al years ago, when he was in the midst of a deal fren­zy worth bil­lions in up­fronts and mile­stones.

Sev­er­al of his high-pro­file pacts, though, have been un­rav­el­ing or hit with se­vere set­backs. Right on the heels of the im­plo­sion of its $710 mil­lion cash roll of the dice on the in­flam­ma­to­ry bow­el dis­ease drug mon­gersen (GED-301), the FDA hit the com­pa­ny with a refuse-to-file for its would-be MS block­buster ozan­i­mod.

Scott Smith

In re­sponse, Alles has en­gi­neered some big changes at Cel­gene. Just days be­fore Golumbes­ki’s of­fi­cial de­par­ture, COO Scott Smith head­ed out the ex­its, leav­ing Alles in charge of every­thing from clin­i­cal de­vel­op­ment to reg­u­la­to­ry, the all-im­por­tant hema­tol­ogy and on­col­o­gy fran­chise as well as in­flam­ma­tion and im­munol­o­gy.


 

MedTech clinical trials require a unique regulatory and study design approach and so engaging a highly experienced CRO to ensure compliance and accurate data across all stages is critical to development milestones.

In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign

Avance Clinical is the Australian CRO for international biotechs providing world-class clinical research services with FDA-accepted data across all phases. With Avance Clinical, biotech companies can leverage Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend. The CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval for the past 24 years. The company has been recognized for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award and a finalist in Informa Pharma’s Best CRO award for 2022.

Bernat Olle, Vedanta Biosciences CEO

Cit­ing 'chal­leng­ing eco­nom­ic en­vi­ron­ment,' PhI­II-ready mi­cro­bio­me biotech lays off 20% of staffers

The market downturn isn’t just sweeping up public biotechs.

Vedanta Biosciences, a developer of oral drugs derived from the human microbiome, is laying off about 20% of its staff — an unfortunately common occurrence these days. But CEO Bernat Olle took the unusual step of sharing the decision on LinkedIn and offering to connect the employees being let go with any company that’s hiring in their areas.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.

Tony Coles, Cerevel CEO

Cerev­el takes the pub­lic of­fer­ing route, with a twist — rais­ing big mon­ey thanks to ri­val da­ta

As public biotechs seek to climb out of the bear market, a popular strategy to raise cash has been through public offerings on the heels of positive data. But one proposed raise Wednesday appeared to take advantage not of a company’s own data, but those from a competitor.

Cerevel Therapeutics plans to raise $250 million in a public offering and another $250 million in debt, the biotech announced Wednesday afternoon, even though it did not report any news on its pipeline. However, the move comes days after rival Karuna Therapeutics touted positive Phase III data in schizophrenia, a field where Cerevel is pursuing a similar program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.

Who are the women blaz­ing trails in bio­phar­ma R&D? Nom­i­nate them for End­points' 2022 spe­cial re­port

Over the past three years, Endpoints News has spotlighted 60 women who have blazed trails and supercharged R&D across the biopharma world. And judging from the response we’ve received, to both our special reports and live events, telling their stories — including any obstacles they may have had to overcome — has inspired our readers in many different ways.

But change takes time, and the fact remains that women are still underrepresented at the upper ranks of the drug-making world.

Hervé Affagard, MaaT Pharma CEO

One year in­to clin­i­cal hold, FDA has more ques­tions about 'pooled' mi­cro­bio­me ther­a­py

The FDA is still wary about a trial testing a microbiome therapy in patients with steroid-resistant acute graft-versus-host disease (aGVHD).

A year after MaaT Pharma’s IND application in the US was first met with a clinical hold, the French biotech said the agency is maintaining the hold. The crux of the matter, MaaT suggested, has to do with the way it puts together its drug candidate, which is administered as an enema (i.e. an injection of fluid into the bowel).

Up­dat­ed: Amid mas­sive re­struc­tur­ing, Bio­gen looks to re­duce phys­i­cal pres­ence in Boston

Biogen is putting a sizable chunk of office and research space in Kendall Square and Weston, MA up for sublease, marking another big change as the biotech grapples with the aftershock of a disastrous and controversial rollout for its Alzheimer’s drug.

The subbleases are “part of Biogen’s overall implementation of the ‘Future of Work,’ which is allowing us to optimize our footprint and reduce the amount of space we occupy, taking into consideration new elements such as the hybrid work model,” Biogen spokesperson Ashleigh Koss wrote in a statement to Endpoints News, adding that the company has had subleases across several buildings for years.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.

Mathai Mammen (Rob Tannenbaum, Endpoints News at BIO 2018)

Math­ai Mam­men makes an abrupt ex­it as head of the big R&D group at J&J

In an after-the-bell shocker, J&J announced Monday evening that Mathai Mammen has abruptly exited J&J as head of its top-10 R&D group.

Recruited from Merck five years ago, where the soft-spoken Mammen was being groomed as the successor to Roger Perlmutter, he had been one of the top-paid R&D chiefs in biopharma. His group spent $12 billion last year on drug development, putting it in the top 5 in the industry.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er launch­es re­bate pro­gram for rare dis­ease pa­tients who have to stop tak­ing Panzy­ga

Pfizer is launching its second-ever rebate program, this time for Panzyga, its treatment for a rare neurological disease of the peripheral nerves.

The program began last month, according to STAT which first reported the news, and offers a refund of out-of-pocket costs for patients who must discontinue their course before the fifth treatment for “clinical reasons.”

Panzyga was approved back in 2018 to treat primary immunodeficiency (PI) in patients two years and older and chronic immune thrombocytopenia (cITP) in adults. It has since picked up an indication in chronic inflammatory demyelinating polyneuropathy (CIDP), a condition that’s characterized by weakness of the arms or legs, tingling or numbness, and a loss of deep tendon reflexes, according to the NIH.

Horizon's back-to-school campaign for children with cystinosis includes an all about me poster as part of a care package box.

Hori­zon read­ies kids and fam­i­lies for back to school with week­long ac­tiv­i­ties around rare dis­ease cysti­nosis

Going back to school is usually a bumpy readjustment from summer freedom for all kids, but especially for kids with chronic health conditions. Horizon Therapeutics is hoping to help smooth the way for some who have the rare disease cystinosis. Cystinosis is a genetic disease that causes the amino acid cystine to build up in different tissues and organs.

The “Gear Up” for school campaign is running all week with different online and at-home events and activities for families and children with cystinosis. Each family who signed up receives a care package mailed to their home including an activity coloring book “Michael’s Show-and-Tell.” The book tells Michael’s story about living with cystinosis while offering kids matching, coloring and finding object games along with information.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.